I think you will find those words are the accepted norms for the results.
It is not the fault of the company that shareholders don't understand the significance of a result that gives 11 stablised cancers in 15 severe cases (as well as a partial positive result). Very few people with any understanding would not regard this as outstanding.
The real worry is that a pharma will make a quick t/o at much below what we are worth.
Ann: Encouraging data from PTX-200 ovarian cancer trial, page-84
-
- There are more pages in this discussion • 88 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
